The trial is an open-label, multi-center safety and preliminary efficacy trial of epcoritamab (EPKINLY™) in Japanese participants with relapsed, progressive or refractory B-cell lymphomas and Japanese participants with B-cell lymphomas that have achieved partial response (PR) or complete response (CR) following prior standard of care (SOC). The trial consists of two parts: Part 1, dose escalation (phase 1), and Part 2, expansion (phase 2). The purpose of the dose-escalation part of the trial is to determine the maximum tolerated dose (MTD) and the recommended Phase-2 dose (RP2D), as well as to establish the safety profile of epcoritamab in Japanese participants with relapsed, progressive or refractory B-cell lymphoma and Japanese participants with B-cell lymphomas that have achieved PR or CR. In the expansion part, additional participants will be treated with epcoritamab, at the RP2D and the purpose is to further explore and determine the safety and efficacy of epcoritamab. Part 2 of the trial will be initiated once the RP2D has been determined in Part 1. In Part 2, epcoritamab is investigated as a monotherapy and in combination with other SOC agents.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Part 1: Number of Participants with Treatment-emergent Adverse Events (TEAEs)
Timeframe: From first dose until the end of the safety follow-up period (60 days after last dose), up to approximately 5 years
Part 1: Number of Participants with Dose Limiting Toxicities (DLTs)
Timeframe: DLTs are assessed during the first cycle (28 days) in each cohort
Part 2, Arm 1: Objective Response Rate (ORR)
Timeframe: Up to 1.5 years
Part 2, Arms 2-4: Number of Participants with DLTs
Timeframe: DLTs are assessed during the first cycle (28 days) in arms 2-4
Part 2, Arms 2-5: Number of Participants with TEAEs
Timeframe: From first dose until the end of the safety follow-up period (60 days after last dose), up to approximately 5 years